Regaal Resources standalone Q1 FY27: revenue down 18% YoY on capacity ramp-up, PAT up 47%
PAT +47% YoY · revenue -18.02% · margins expanding
₹202.15 Cr
-18.02% YoY
₹13.33 Cr
+47% YoY
6.58%
+2.9pp YoY
₹1.3
Regaal Resources' standalone Q1 FY27 (quarter ended June 30, 2026) revenue fell 18.0% YoY to ₹202.15 Cr (₹246.57 Cr in Q1 FY26) and 17.4% sequentially from ₹244.61 Cr in Q4 FY26. PAT nonetheless rose 47.0% YoY to ₹13.33 Cr (₹9.07 Cr a year ago), though it slipped 19.4% QoQ from ₹16.54 Cr. Basic EPS was ₹1.30 versus ₹1.10 YoY and ₹1.63 QoQ. No consensus estimates for the quarter turned up in a search (this is a small-cap, ~₹847 Cr market cap per a Univest preview), so vsStreet is unknown; management itself has issued no formal FY27 guidance, having explicitly deferred it until a quarter of stabilized post-expansion operations, expected by end of H1 FY27 — so this print has no numeric bar to be graded against, only that qualitative marker.
Q1 FY-2027 vs prior quarters
On margins, OPM (EBITDA/revenue, adding back finance cost and depreciation, excluding other income) expanded to roughly 15.3% from 9.9% a year ago, and NPM to 6.6% from 3.7%, even with revenue down — the gain traces to lower raw-material intensity (cost of materials plus stock-in-trade purchases fell to about 66% of revenue from 72% YoY), partly offset by higher other expenses (₹41.53 Cr vs ₹30.00 Cr YoY) tied to the capacity build-out. Sequentially, though, NPM eased slightly from 6.75% in Q4 FY26 as PAT fell faster than revenue. Since neither this quarter nor the year-ago quarter carries an exceptional item, the 47% YoY PAT growth is on a clean, comparable base.
What the summary numbers don't show
No exceptional items this quarter (unlike FY26's full year, which carried a ₹6.66 Cr SGST-subsidy exceptional provision); YoY PAT growth is on a clean base both periods.
Management is refraining from providing formal earnings guidance for FY27 until a quarter of stabilized operations post-expansion commissioning, expected by the end of H1 FY27. They anticipate significant revenue growth, potentially doubling existing levels, driven by the new 1,650 TPD capacity and a substantial increa
— This quarter: missed
The revenue dip lines up with note 6 in the filing: during the quarter the company commissioned its expanded maize-crushing capacity from 825 TPD to 1,650 TPD, plus new 180 TPD Liquid Glucose and 50 TPD Maltodextrin Powder facilities, and lifted captive co-generation power from 7.1 MW to 15.8 MW — commissioning disruption during ramp-up is the likely driver of softer volumes even as the company enters an expanded capacity base. Against May 2026 concall commentary anticipating "significant revenue growth, potentially doubling" FY27 revenue and a value-added product mix rising from 2-3% to 20-25%, this quarter shows no sign of that inflection yet — expected given the mid-quarter commissioning timeline, but it leaves the FY27 growth story unproven one quarter in. Post quarter-end, the company allotted 2.70 lakh ESOP shares on July 21, 2026, lifting paid-up capital to ₹51.50 Cr from ₹51.36 Cr. No press release or management commentary beyond the regulatory filing was available to corroborate this framing further.
W1
Whether Q2 FY27 shows the revenue ramp management anticipated now that 1,650 TPD crushing, LG and MDP lines are commissioned — management flagged stabilization 'by end of H1 FY27.'
W2
Value-added product mix, guided to rise from 2-3% in FY26 to 20-25% in FY27, as new LG/MDP capacity ramps.
W3
Margin trajectory (OPM ~15.3% this quarter) as the ₹140 Cr further VAP/co-gen capex plays out and utilization improves.
Standalone-only filing (no consolidated statement present). Figures reported in Rs. Millions, converted to Cr by dividing by 10. No exceptional item this quarter or in year-ago quarter (FY26 full-year exceptional item of Rs.66.57mn / Rs.6.66 Cr, an SGST-subsidy provision, sits only in the annual column). EPS is basic, not annualised, per filing convention.